Elicio Therapeutics Inc.: Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival ("DFS") event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration ("FDA") on ...
Edible garden targets profitability in 2025 with expanded product focus and improved margins
Discover key insights from Edible Garden's Q4 2024 earnings call, highlighting 181.3% profit growth, strategic shifts, and plans for global expansion in 2025.
The Manila Times14h
Edible Garden Reports 181.3% Year-over-Year Gross Profit Increase for 2024
Edible Garden AG Incorporated ("Edible Garden” or the "Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment ...
Edible Garden reports Q4 EPS ($10.34) vs ($263.52) last year
Reports Q4 revenue $3.872M vs $4.084M last year. “We are pleased to report a 181.3% increase in gross profit for 2024 along with a significant ...
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis ...
Money changes in April: Impact on GST, credit cards & other transactions
Starting April 1, investors will be able to store their demat account holding statements and consolidated account statements ...